View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Catalyst Pharmaceuticals Inc: 1 director

A director at Catalyst Pharmaceuticals Inc sold/sold after exercising options 26,746 shares at 23.253USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan...

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...

 PRESS RELEASE

Appian Corporation to Present at the Barclays 23rd Annual Global Techn...

Appian Corporation to Present at the Barclays 23rd Annual Global Technology Conference MCLEAN, Va., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN), today announced that Serge Tanjga, Chief Financial Officer, will present at the Barclays 23rd Annual Global Technology Conference in San Francisco, CA. The fireside chat is scheduled for Wednesday, December 10, 2025 at 8:40am Pacific Time and will be webcast live at the following link:  Replays of the fireside chat will be available for a limited time under the “News and Events” section of the Company’s investor relations website at ...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in the Bank of America CNS The...

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Mo...

 PRESS RELEASE

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-...

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced it ranked 304 on the ™, a ranking of the 500 fastest-growing tec...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthca...

Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in Citi’s 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 20...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Appian Announces Third Quarter 2025 Financial Results

Appian Announces Third Quarter 2025 Financial Results Third quarter cloud subscriptions revenue increased 21% year-over-year to $113.6 millionThird quarter total revenue increased 21% year-over-year to $187.0 million MCLEAN, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue: Cloud subscriptions revenue was $113.6 million, up 21% compared to the third quarter of 2024. Total subscriptions revenue, which includes sales of our cloud subscriptio...

 PRESS RELEASE

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results ...

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM E...

 PRESS RELEASE

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to...

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to be na...

 PRESS RELEASE

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare...

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: November 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 29, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Result...

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market c...

 PRESS RELEASE

Appian To Announce Third Quarter 2025 Financial Results on November 6,...

Appian To Announce Third Quarter 2025 Financial Results on November 6, 2025 MCLEAN, Va., Oct. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: APPN) today announced that it will release financial results for the third quarter ended September 30, 2025 before the U.S. financial markets open on Thursday, November 6, 2025. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can join the call, us...

 PRESS RELEASE

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientifi...

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that data developed by or in conjunction with the company will be presented at several upcoming scientific conferences, details of which are listed below. "At Catalyst, everything begins with patients. ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch